secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibrx Biosciences, Inc. (INBX)
CIK:        0002007919
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001104659-24-066645
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 3.03, 5.03, 5.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibrx Biosciences completes spin-off from RemainCo, lists 14.5M shares outstanding
--------------------------------------------------------------------------------

- Completed spin-off on May 29, 2024; 92% of Inhibrx Biosciences shares distributed to RemainCo shareholders at 1:4 ratio.
- As of May 30, 2024, 14,475,904 shares of common stock outstanding post-distribution.
- Issued warrants for up to 991,849 shares at $0.0001 exercise price, no expiration; also issued 1,838 shares to Oxford Finance.
- Entered registration rights agreement requiring filing of resale registration statement within 10 business days.
- Entered employment agreements with CEO Lappe ($695,250 base), CFO Eckelman ($535,600), and CAO Deck ($460,100) with 12-month severance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/0001104659-24-066645-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/tm243190d19_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-066645

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer